Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAbcine Inc.

www.pharmabcine.com

Latest From PharmAbcine Inc.

Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies

The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.

Financing StartUps and SMEs

Interview: PharmAbcine's Hopes Rise As Tanibirumab Set For Keytruda Combo Trials

PharmAbcine CEO Jin-San Yoo talks to Scrip about the company’s overseas clinical trial strategy, pipeline assets, and ambitions for lead candidate TTAC-0001, which the company sees as superior to Avastin. The Korean biotech, which is engaged in various global collaborations on its investigative antibody drugs, hopes that tie-ups can lead to bigger outcomes going forward.

South Korea Biologics

Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018

Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.

Commercial Financing

Interview: Fledgling ABL Bio And Its Global Ambitions In Bispecific Antibodies

South Korea’s ABL Bio is tackling cancer and neurodegenerative diseases with its broad bispecific antibody pipeline and CEO Sang Hoon Lee outlines the firm’s multi-collaboration and licensing strategy.

Research & Development South Korea
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • PharmAbcine Inc.
  • Senior Management
  • Jin-San Yoo, PhD, Pres. & CEO
  • Contact Info
  • PharmAbcine Inc.
    Phone: (82) 42 863 2017 9
    461-8, Daejeon BioventureTown
    Jeonmin-Dong
    Yuseong-Gu, Daejeon,
    South Korea
UsernamePublicRestriction

Register